Summit Therapeutics (SMMT)

Executive Summary

Summit Therapeutics is a clinical-stage biopharmaceutical company advancing ivonescimab, a novel PD-1/VEGF bispecific antibody, across multiple oncology indications. Ivonescimab has demonstrated promising efficacy in non-small cell lung cancer (NSCLC) and colorectal cancer, with several Phase 3 trials underway. The company's pipeline includes Phase 2/3 studies in endometrial, cervical, salivary gland, and head and neck cancers, as well as glioblastoma and triple-negative breast cancer. With a market capitalization of approximately $11 billion, Summit is well-capitalized to advance its clinical programs. Key upcoming data readouts from pivotal trials could significantly impact the stock, as ivonescimab has the potential to become a best-in-class immunotherapy. The company's focus on both solid tumors and infectious diseases (though the latter pipeline appears terminated) provides diversification, though its near-term value hinges on ivonescimab's success.

Upcoming Catalysts (preview)

• H2 2026Phase 3 ivonescimab + bevacizumab in metastatic colorectal cancer (CRC) interim data70% success
• H1 2027Phase 3 ivonescimab + pembrolizumab in NSCLC top-line results65% success
• Q1 2027Phase 2 ivonescimab in endometrial/cervical cancer data60% success